Lilly’s new GLP-1 pill is off to a ‘robust’ start

The Big Market Report Take

Lilly’s new GLP-1 pill had 1,390 prescriptions in its first week on the market.

Read full article on MarketWatch Follow on X Follow on Bluesky Back to today's briefing

Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →

Never miss a story

Lilly’s new GLP-1 pill is off to a ‘robust’ start

More from this section